Novartis Fights Bid To Invalidate Blood Transfusion Drug IP
Novartis AG has taken a stand against generic-drug maker Teva's claims that the pharmaceutical giant's intellectual property for a blood transfusion medicine should be revoked, denying that prior medical advances would...To view the full article, register now.
Already a subscriber? Click here to view full article